MX364314B - Nuevo sulfato de dextrano. - Google Patents

Nuevo sulfato de dextrano.

Info

Publication number
MX364314B
MX364314B MX2017006122A MX2017006122A MX364314B MX 364314 B MX364314 B MX 364314B MX 2017006122 A MX2017006122 A MX 2017006122A MX 2017006122 A MX2017006122 A MX 2017006122A MX 364314 B MX364314 B MX 364314B
Authority
MX
Mexico
Prior art keywords
dextran sulfate
salt
sulfate
interval
average
Prior art date
Application number
MX2017006122A
Other languages
English (en)
Other versions
MX2017006122A (es
Inventor
Bruce Lars
Brasen Ulf
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of MX2017006122A publication Critical patent/MX2017006122A/es
Publication of MX364314B publication Critical patent/MX364314B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/721Dextrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02Dextran; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un sulfato de dextrano, o una sal del mismo, tiene un numero de peso molecular promedio (Mn) según lo medido por espectroscopia de RMN dentro de un intervalo de 1850 y 2000 Da. El sulfato de dextrano, o la sal del mismo, también tiene un número de sulfato promedio por unidad de glucosa dentro de un intervalo de 2.5 y 3.0. Además, una sulfatacion promedio de la posición C2 en las unidades de glucosa del sulfato de dextrano, o la sal del mismo, es de por lo menos 90%. El sulfato de dextrano tiene efectos biológicos mejorados y/o toxicidad reducida en comparación con moléculas de sulfato de dextrano similares disponibles en el mercado.
MX2017006122A 2014-11-11 2015-11-10 Nuevo sulfato de dextrano. MX364314B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1451349A SE538503C2 (en) 2014-11-11 2014-11-11 New dextran sulfate
PCT/SE2015/051188 WO2016076780A1 (en) 2014-11-11 2015-11-10 New dextran sulfate

Publications (2)

Publication Number Publication Date
MX2017006122A MX2017006122A (es) 2017-08-10
MX364314B true MX364314B (es) 2019-04-22

Family

ID=55954726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006122A MX364314B (es) 2014-11-11 2015-11-10 Nuevo sulfato de dextrano.

Country Status (30)

Country Link
US (2) US10407514B2 (es)
EP (1) EP3217988B1 (es)
JP (1) JP6251459B1 (es)
KR (1) KR101834710B1 (es)
CN (1) CN107106595B (es)
AU (1) AU2015347361B2 (es)
BR (1) BR112017009752B1 (es)
CA (1) CA2967264C (es)
CY (1) CY1121336T1 (es)
DK (1) DK3217988T3 (es)
EA (1) EA032383B1 (es)
ES (1) ES2706287T3 (es)
HR (1) HRP20190073T1 (es)
HU (1) HUE042806T2 (es)
IL (1) IL251871A (es)
LT (1) LT3217988T (es)
MX (1) MX364314B (es)
MY (1) MY181598A (es)
NZ (1) NZ731141A (es)
PH (1) PH12017500799A1 (es)
PL (1) PL3217988T3 (es)
PT (1) PT3217988T (es)
RS (1) RS58222B1 (es)
SA (1) SA517381478B1 (es)
SE (1) SE538503C2 (es)
SG (1) SG11201703198PA (es)
SI (1) SI3217988T1 (es)
SM (1) SMT201900032T1 (es)
TR (1) TR201900334T4 (es)
WO (1) WO2016076780A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212708A1 (en) 2017-05-17 2018-11-22 Tx Medic Ab Treatment of glaucoma
ES2777836T3 (es) 2017-05-17 2020-08-06 Tx Medic Ab Tratamiento del glaucoma
CA3074987A1 (en) 2017-09-08 2019-03-14 Tx Medic Ab New use of dextran sulfate
EP3810659A1 (en) * 2018-06-20 2021-04-28 DuPont Industrial Biosciences USA, LLC Polysaccharide derivatives and compositions comprising same
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
SE544015C2 (en) * 2019-06-18 2021-11-02 Tx Medic Ab Allogenic car-t cell therapy
WO2021211043A1 (en) * 2020-04-15 2021-10-21 Tx Medic Ab Treatment of coronavirus infections
GB202008919D0 (en) 2020-06-11 2020-07-29 Univ Birmingham Polysaccharide conpositions and therapeutic gels
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases
US20240082296A1 (en) 2020-10-09 2024-03-14 Tx Medic Ab Treatment of muscle atrophy using dextran sulfate
BR112023021145A2 (pt) * 2021-04-14 2023-12-12 Tx Medic Ab Tratamento de infecções por vírus
CN117157084A (zh) * 2021-10-14 2023-12-01 Tx医生公司 病毒感染的治疗

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141014A (en) * 1960-03-31 1964-07-14 Meito Sangyo Kk Sodium and potassium salts of the dextran sulphuric acid ester having substantially no anticoagulant activity but having lipolytic activity and the method of preparation thereof
JPS4730167Y1 (es) 1967-03-09 1972-09-09
JPS469570Y1 (es) 1968-08-28 1971-04-05
US4221907A (en) 1979-07-09 1980-09-09 American Cyanamid Company Substituted O-α-D and O-β-D-multi-galactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6 α-D-glucopyranoses
US4232150A (en) 1979-07-09 1980-11-04 American Cyanamid Company Oligosaccharide precursors to substituted O-α-D and O-β-D-multigalactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6α-D-glucopyranoses
US4855416A (en) 1983-07-25 1989-08-08 Polydex Pharmaceuticals, Ltd Method for the manufacture of dextran sulfate and salts thereof
EP0240098A3 (en) 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
IL88554A0 (en) 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (es) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JPH08301771A (ja) 1995-03-08 1996-11-19 Shiseido Co Ltd 腎疾患の予防または治療用製剤
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
FR2772382B1 (fr) 1997-12-11 2000-03-03 Solutions Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
CN1347919A (zh) 2000-10-12 2002-05-08 中国科学院生态环境研究中心 带有支链的硫酸酯化寡糖的制备
FR2832708B1 (fr) * 2001-11-29 2004-02-13 Organes Tissus Regeneration Re Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
SE525461C3 (sv) 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
WO2008153962A2 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennylvania Method of reducing tissue loss in pancreatic islet cell transplantation
CA2750188C (en) 2009-02-02 2016-11-29 Otsuka Chemical Co., Ltd. Low-molecular polysulfated hyaluronic acid derivative and compositions containing same
SE537742C2 (sv) 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
CN103554297B (zh) * 2013-10-21 2016-09-07 兰州大学 一种高硫代度红芪多糖硫酸酯的制备方法及其应用
PT3154551T (pt) * 2014-06-12 2019-01-18 Tx Medic Ab A utilização de sulfato de dextrano tendo uma massa molecular média inferior a 10000 da para induzir angiogénese num sujeito

Also Published As

Publication number Publication date
JP2018501332A (ja) 2018-01-18
SI3217988T1 (sl) 2019-02-28
MX2017006122A (es) 2017-08-10
CA2967264C (en) 2018-02-20
KR20170059008A (ko) 2017-05-29
PL3217988T3 (pl) 2019-05-31
US10407514B2 (en) 2019-09-10
US10730960B2 (en) 2020-08-04
EP3217988B1 (en) 2018-10-24
SE538503C2 (en) 2016-08-16
US20180298116A1 (en) 2018-10-18
EA201790856A1 (ru) 2017-09-29
SE1451349A1 (en) 2016-05-12
EP3217988A1 (en) 2017-09-20
PT3217988T (pt) 2019-01-29
NZ731141A (en) 2019-07-26
PH12017500799B1 (en) 2017-10-02
CA2967264A1 (en) 2016-05-19
HUE042806T2 (hu) 2019-07-29
SMT201900032T1 (it) 2019-02-28
KR101834710B1 (ko) 2018-03-05
CY1121336T1 (el) 2020-05-29
RS58222B1 (sr) 2019-03-29
CN107106595A (zh) 2017-08-29
US20190375859A1 (en) 2019-12-12
AU2015347361A1 (en) 2017-05-11
HRP20190073T1 (hr) 2019-03-08
PH12017500799A1 (en) 2017-10-02
LT3217988T (lt) 2019-02-11
ES2706287T3 (es) 2019-03-28
DK3217988T3 (en) 2019-02-04
AU2015347361B2 (en) 2019-01-17
BR112017009752B1 (pt) 2022-12-06
SA517381478B1 (ar) 2020-09-28
SG11201703198PA (en) 2017-05-30
BR112017009752A2 (pt) 2018-02-20
EP3217988A4 (en) 2018-05-30
IL251871A (en) 2017-11-30
EA032383B1 (ru) 2019-05-31
CN107106595B (zh) 2018-10-30
WO2016076780A1 (en) 2016-05-19
TR201900334T4 (tr) 2019-02-21
JP6251459B1 (ja) 2017-12-20
MY181598A (en) 2020-12-29

Similar Documents

Publication Publication Date Title
NZ731141A (en) New dextran sulfate
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
WO2016086036A3 (en) Methods and compositions for 18f-radiolabeling of biologics
NZ718962A (en) Cancer models and associated methods
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
MX367853B (es) Ácido hialurónico entrelazado injertado con dextrán.
WO2015026601A3 (en) Dithiol mucolytic agents
HK1209031A1 (en) Polysaccharide compositions and methods of use
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
Cowan Stability of entire solutions to supercritical elliptic problems involving advection
EP2836147A4 (en) CARTILAGE REPAIR, CONSERVATION AND GROWTH THROUGH STIMULATION OF THE BONE CARTILAGE INTERMEDIATE LAYER AND ADMINISTRATION SYSTEM AND RELATED METHODS THEREFOR
HK1256902A1 (zh) 氯犬尿氨酸的前体药物
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
AR096540A1 (es) Producto regulador de la salubridad en las plantas, procedimiento de obtención y uso del mismo
WO2015123439A3 (en) Methods of promoting neuroblast differentiation and treating neuroblastoma and of providing a prognosis for subjects with neuroblastoma
RU2014134634A (ru) Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола
Chen et al. On the Road to Conquering Cancer with You: Notes on the New Look of Our Publication
EA201700037A1 (ru) Производные 2н-хромена в качестве анальгезирующих средств
TH155839S (th) อุปกรณ์ปรับระดับ
Chirawatkul Analysis of risk factors by adjusted odds ratio
Fofiu THE AGEING PHENOMENON
HK1241296A1 (en) Interleukin-15 compositions and uses thereof
Рыфф et al. ÂÎÇÌÎÆÍÎÑÒЬ ÈÑÏÎËЬÇÎÂÀÍÈß ÁÈÎÒÅХÍÎËÎÃÈЧÅÑÊÎÃÎ ÌÅÒÎÄÀ ÄËß ÎÏÐÅÄÅËÅÍÈß ÑÎËÅÓÑÒÎЙЧÈÂÎÑÒÈ ÂÈÍÎÃÐÀÄÀ
TH125371S (th) หน้าตัดราง
TH111430S (th) บานประตู

Legal Events

Date Code Title Description
FG Grant or registration